Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Mesenchymal stem cells therapy for Ischaemic stroke: Mechanism and progress.

Li S., Huang H., Deng W., Wu Q., Zhao Y., Zhai L.

Clinical Trial on Stroke Research, published in Exp Neurol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Exp Neurol (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
42035844
DOI
10.1016/j.expneurol.2026.115795

Abstract (original English)

Ischaemic stroke is a leading global cause of death and long-term disability. Current acute interventions, notably thrombolysis and mechanical thrombectomy, are limited by narrow therapeutic windows and primarily focus on vascular recanalization. These approaches often fail to address the sustained neurovascular injury, persistent inflammation, and insufficient endogenous repair that underlie long-term functional impairment. In this context, mesenchymal stem cells (MSCs) have emerged as a highly promising regenerative strategy for ischemic stroke, targeting the multifaceted pathophysiology beyond acute revascularization. Sourced predominantly from bone marrow, umbilical cord, and adipose tissue, MSCs exert effects primarily through their multimodal paracrine actions. They home to the injury site and orchestrate the local immune microenvironment by dampening excessive inflammation and promoting a shift in macrophages toward a pro-repair phenotype. Furthermore, MSCs enhance neurovascular plasticity and tissue regeneration through the release of bioactive factors and extracellular vesicles. This review provides a comprehensive analysis of MSCs sources and their multimodal mechanisms of action, synthesizes preclinical evidence and clinical trial advancements in stroke, discusses persisting translational challenges, and outlines future directions in the field. Collectively, MSCs-bas

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansIschemic StrokeMesenchymal Stem Cell TransplantationAnimalsMesenchymal Stem CellsBrain Ischemia

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research